Search results
The Coronavirus SARS-CoV-2 (COVID-19) by nucleic acid amplification test is for in vitro diagnostic use under the FDA Emergency Use Authorization (EUA) for U.S. laboratories certified under CLIA to perform high complexity tests. This test has not been FDA cleared or approved.
Details. LOINC®. Back to Top. 2019 Novel Coronavirus (COVID-19), NAA. TEST: 139900. CPT: 87635. Print Share Include LOINC® in print. Synonyms. 2019 Novel Coronavirus. COVID-19. SARS-CoV-2. Special Instructions. Please note: Labcorp does not currently collect specimens for this test.
May 12, 2023 · Amplifying those nucleic acids enables NAATs to detect very small amounts of SARS-CoV-2 RNA in a specimen, making these tests highly sensitive for diagnosing COVID-19. In other words, NAATs can reliably detect small amounts of SARS-CoV-2 and are unlikely to return a false-negative result of SARS-CoV-2.
Jan 9, 2024 · The purpose of the test. Whether the test is a nucleic acid amplification test (NAAT), such as a PCR test, or an antigen test. Who will pay for the test. How the test will be performed. How and when they will receive test results. How to understand what the results mean. What actions need to happen after someone has a negative or positive result.
Dec 20, 2023 · For diagnosing current SARS-CoV-2 infection, the CDC recommends using a specimen from the upper respiratory tract (e.g., nasal, nasopharyngeal). 5 Testing lower respiratory tract specimens is also an option in certain circumstances (e.g., in those receiving mechanical ventilation).
Apr 15, 2021 · SARS-CoV-2 is the novel coronavirus that causes COVID-19. The spectrum of asymptomatic, presymptomatic, and symptomatic SARS-CoV-2 transmission presents challenges for evaluating...
Types of molecular tests being developed for SARS-CoV-2. Current antigen and molecular tests with FDA EUA Status. What is needed to perform a molecular test? Molecular tests require samples—such as nasopharyngeal surface cells or sputum/saliva—that are likely to contain the virus.
